<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are at enhanced risk for macro- and microvascular complications </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0002871'>Albuminuria</z:mp> and/or reduced kidney function further enhances the vascular risk </plain></SENT>
<SENT sid="2" pm="."><plain>We initiated the <z:chebi fb="0" ids="601027">Aliskiren</z:chebi> Trial in Type 2 <z:mp ids='MP_0002055'>Diabetes</z:mp> Using Cardio-Renal Endpoints (ALTITUDE) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="601027">Aliskiren</z:chebi>, a novel direct renin inhibitor, which lowers plasma renin activity, may thereby provide greater cardio-renal protection compared with <z:chebi fb="0" ids="35457">angiotensin converting enzyme inhibitor</z:chebi> (ACEi) or angiotensin receptor blocker (ARB) alone </plain></SENT>
<SENT sid="4" pm="."><plain>MATERIALS AND METHODS: ALTITUDE is a randomized, double-blind, placebo-controlled study in high risk type 2 diabetic patients receiving <z:chebi fb="0" ids="601027">aliskiren</z:chebi> 300 mg once daily or placebo added to recommended cardio-renal protective treatment including ACEi or ARB, but not both </plain></SENT>
<SENT sid="5" pm="."><plain>The number of patients randomized was 8606 </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Baseline characteristics (median, IQR) are: age 65 (58, 72) years, male 68%, BMI 29.1 (25.7, 32.2) kg/m(2), <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> 47.9%, blood pressure 134.7 (126, 150)/74.3 (67, 81) mmHg, HbA(1c) 7.5 (6.6, 8.6)%, <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> 2.4 (1.9, 3.0) mmol/L, <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> 130 (119, 143) g/L, serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> 115 (91, 137) Âµmol/L, eGFR 51.7 (42, 65) ml/min per 1.73 m(2), geometric mean UACR 198.9 (52, 2886) mg/g and frequency of micro/macroalbuminuria 25.7% and 58.2% </plain></SENT>
<SENT sid="7" pm="."><plain>ALTITUDE is an event-driven trial to continue until 1628 patients experience a primary cardiovascular-renal event </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: ALTITUDE will determine the potential cardio-renal benefit and safety of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> in combination with ACEi or ARB in high risk patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>